| 0.47 -0.07 (-12.96%) | 05-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.72 | 1-year : | 0.84 |
| Resists | First : | 0.61 | Second : | 0.72 |
| Pivot price | 0.49 |
|||
| Supports | First : | 0.41 | Second : | 0.29 |
| MAs | MA(5) : | 0.48 |
MA(20) : | 0.47 |
| MA(100) : | 0.72  |
MA(250) : | 1.12 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 66 |
D(3) : | 60.4 |
| RSI | RSI(14): 51.9 | |||
| 52-week | High : | 3.06 | Low : | 0.15 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CYAD ] has closed below upper band by 37.8%. Bollinger Bands are 41.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.52 - 0.52 | 0.52 - 0.53 |
| Low: | 0.51 - 0.52 | 0.52 - 0.52 |
| Close: | 0.52 - 0.52 | 0.52 - 0.52 |
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Thu, 04 Apr 2024
Celyad Oncology Reports Full Year 2023 Financial Results and Recent Business Highlights - Business Wire
Thu, 08 Feb 2024
Celyad Oncology announces intention to terminate SEC reporting obligations - Yahoo Finance
Tue, 16 Jan 2024
Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook - GlobeNewswire
Mon, 04 Dec 2023
Celyad Announces Management Change - PharmiWeb.com
Thu, 07 Sep 2023
Celyad Oncology SA: Publication of a Transparency Notification Received From Fortress Investment Group LLC - Business Wire
Fri, 24 Mar 2023
Celyad Oncology appoints Georges Rawadi as its new CEO - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 23 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 29.1 (%) |
| Shares Short | 130 (K) |
| Shares Short P.Month | 151 (K) |
| EPS | -1.48 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.18 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -25.5 % |
| Return on Equity (ttm) | -170.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.87 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -28 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -0.36 |
| PEG Ratio | 0 |
| Price to Book value | 2.73 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|